prothymosin alpha is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | 28 residues; not a small-molecule compound |
| Molecular mass | About 3,106 Da | Monoisotopic mass of the unmodified chain |
| N-terminal group | Acetylated serine | Present in both native and synthetic forms |
| Secondary structure | Disulfide-constrained loop | One bridge between two cysteine residues |
| Typical source | Solid-phase synthesis | Early isolates came from bovine thymus extracts |
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
A norepinephrine and dopamine disinhibitor (NDDI or NDD) is a drug that acts at specific sites to disinhibit downstream norepinephrine and dopamine release in the brain. Agomelatine, an antidepressant which disinhibits norepinephrine and dopamine release in the frontal cortex by antagonizing 5-HT2C receptors, was the first drug to be described as an NDDI. While many other drugs also antagonize 5-HT2C receptors to some degree or another, they tend to be very non-specific in their actions, and as a result, the term "NDDI" has generally, though not always (for instance, fluoxetine has been called an NDDI in addition to SSRI due to its (weak) blockade of 5-HT2C), been reserved for describing newer, more selective agents in which disinhibition of norepinephrine and dopamine release is their primary mechanism of action. Another drug that has been referred to as an NDDI in the medical literature is flibanserin, which is approved as a treatment for hypoactive sexual desire disorder in premenopausal women. Flibanserin disinhibits norepinephrine and dopamine release in the prefrontal cortex by activating postsynaptic 5-HT1A receptors in this area. Aside from agomelatine, fluoxetine, flibanserin, mianserin and mirtazapine, as of present, no other drugs have been described as NDDIs in the medical literature, despite the fact that many other existing drugs possess effects consistent with those of the definition of an NDDI. In any case, more drugs labeled specifically as NDDIs may be seen in the future.
Some of the steel transmitter towers remain, although the wooden receiver towers have all been demolished. The remaining towers have various new uses and in some cases are now protected as listed buildings by order of English Heritage. One such 360-foot-high (110 m) transmitter tower can now be found at the BAE Systems facility at Great Baddow in Essex, on the former Marconi Research Centre site. It originally stood at RAF Canewdon in Essex and was moved to Great Baddow in 1956. This is the only surviving Chain Home tower still in its original, unmodified form with cantilever platforms at 50 ft, 200 ft and 360 ft, and in 2019 was given Grade II listed status. Swingate transmitting station in Kent (originally AMES 04 Dover) has two original towers (three until 2010) which are used for microwave relay; the towers lost their platforms in the 1970s. RAF Stenigot in Lincolnshire has another, almost complete tower, without its top platforms; it is used for training aerial erectors. The only original Chain Home site which is still used as a military radar station is RRH Staxton Wold in North Yorkshire, although there are no remnants of the 1937 equipment as it was completely cleared and remodelled for the ROTOR replacement, the Linesman/Mediator system, in 1964. The 240-foot timber receiver towers were some of the tallest wooden structures ever built in Britain. Two of these wooden towers were still standing in 1955, at Hayscastle Cross. Unlike the transmitter tower pictured here, those at Hayscastle Cross were guyed.
In 1960 Dyson wrote a short paper for the journal Science titled "Search for Artificial Stellar Sources of Infrared Radiation". In it he speculated that a technologically advanced extraterrestrial civilization might surround its native star with artificial structures to maximize the capture of the star's energy. Eventually, the civilization would enclose the star, intercepting electromagnetic radiation with wavelengths from visible light downward and radiating waste heat outward as infrared radiation. One method of searching for extraterrestrial civilizations would be to look for large objects radiating in the infrared range of the electromagnetic spectrum.
===== MeSH D08.811.913.225 – alkyl and aryl transferases (EC 2.5) ===== MeSH D08.811.913.225.224 – cysteine synthase MeSH D08.811.913.225.300 – dihydropteroate synthase MeSH D08.811.913.225.400 – dimethylallyltranstransferase MeSH D08.811.913.225.431 – farnesyl-diphosphate farnesyltransferase MeSH D08.811.913.225.437 – farnesyltranstransferase MeSH D08.811.913.225.443 – geranylgeranyl-diphosphate geranylgeranyltransferase MeSH D08.811.913.225.450 – geranyltranstransferase MeSH D08.811.913.225.500 – glutathione transferase MeSH D08.811.913.225.500.500 – glutathione S-transferase pi MeSH D08.811.913.225.575 – hydroxymethylbilane synthase MeSH D08.811.913.225.650 – methionine adenosyltransferase MeSH D08.811.913.225.735 – 3-phosphoshikimate 1-carboxyvinyltransferase MeSH D08.811.913.225.750 – riboflavin synthase MeSH D08.811.913.225.825 – spermidine synthase MeSH D08.811.913.225.912 – spermine synthase
== Research facilities == RCB has established facilities in its interim campus at Gurgaon where it is functioning. Centre is expected to expand further when it moves to its permanent campus in Faridabad, within the NCR Biotech Science Cluster, later this year. RCB has established major specialized facilities that include: high resolution optical imaging (Atomic Force Microscopy, Confocal Microscopy, Fluorescence Microscopy), synthesis chemistry facilities, Protein sequencer, Protein purification systems, biophysical (Isothermal Titration Calorimetry, Differential Scanning Calorimetry, Circular Dichroism, SPR, NMR, FTIR, Dynamic Light Scattering), structural biology (Crystallization Robotics, X-ray Diffraction), proteomics (ABSciEx Triple TOF 5600), flow cytometry, plant, bacterial and animal cell/ tissue culture facilities, tissue sectioning and insect culture facilities. In addition, researchers at RCB have access to the Advanced Technology Platform Center (ATPC) of the Biotech Science Cluster Faridabad. The ATPC already houses an operational flow cytometry and proteomics facilities. Other high-end facilities planned to be operational in near future include complete optical imaging, electron microscopy and next-generation sequencing.
Sources: en.wikipedia.org
One-color light is well suited for traffic lights and signals, exit signs, emergency vehicle lighting, ships' navigation lights, and LED-based Christmas lights. Because of their long life, fast switching times, and visibility in broad daylight due to their high output and focus, LEDs have been used in automotive brake lights and turn signals. The use in brakes improves safety, due to a great reduction in the time needed to light fully, or faster rise time, about 200 milliseconds faster than an incandescent bulb. This gives drivers behind more time to react. In a dual intensity circuit (rear markers and brakes) if the LEDs are not pulsed at a fast enough frequency, they can create a phantom array, where ghost images of the LED appear if the eyes quickly scan across the array. White LED headlamps are beginning to appear. Using LEDs has styling advantages because LEDs can form much thinner lights than incandescent lamps with parabolic reflectors. Due to the relative cheapness of low output LEDs, they are also used in many temporary uses such as glowsticks and throwies. Artists have also used LEDs for LED art.
In contrast to the maternal bond, paternal bonds tend to vary over the span of a child's development in terms of both strength and stability. In fact, many children now grow up in fatherless households and do not experience a paternal bond at all. In general, paternal bonding is more dominant later in a child's life after language develops. Fathers may be more influential in play interactions as opposed to nurturance interactions. Father–child bonds also tend to develop with respect to topics such as political views or money, whereas mother–child bonds tend to develop in relation to topics such as religious views or general outlooks on life. In 2003, a researcher from Northwestern University in Illinois found that progesterone, a hormone more usually associated with pregnancy and maternal bonding, may also control the way men react towards their children. Specifically, they found that a lack of progesterone reduced aggressive behavior in male mice and stimulated them to act in a fatherly way towards their offspring.
Sterilization of Latinas has targeted women of different Latin American identities, including those from Puerto Rico and Mexico for many years in the United States. There is a significant history of such sterilization practices being conducted involuntarily, in a coerced or forced manner, as well as in more subtle forms such as that of constrained choice. Coerced sterilization is defined as any sterilization procedure performed without the patient's full, free, and informed consent. This includes procedures carried out through misinformation, language barriers, or under conditions of institutional pressure. The sterilization of Latinas in the United States is rooted in eugenic ideology and racial discrimination. It has a long history of targeting marginalized groups including women of ethnic and racial minorities, women with disabilities, women with HIV and poor women. Coercive sterilization has also been widley recognized as a violation of fundamental human rights and bodily autonomy. Additionally, forced sterilization was permissible by multiple states throughout various periods in the 20th century. Issues of state sterilization have persisted as recently as September 2020. Some sources credit the practice to theories of racial eugenics.
==== Binding capacity ==== Proponents of both agarose and magnetic beads can argue whether the vast difference in the binding capacities of the two beads favors one particular type of bead. In a bead-to-bead comparison, agarose beads have significantly greater surface area and therefore a greater binding capacity than magnetic beads due to the large bead size and sponge-like structure. But the variable pore size of the agarose causes a potential upper size limit that may affect the binding of extremely large proteins or protein complexes to internal binding sites, and therefore magnetic beads may be better suited for immunoprecipitating large proteins or protein complexes than agarose beads, although there is a lack of independent comparative evidence that proves either case. Some argue that the significantly greater binding capacity of agarose beads may be a disadvantage because of the larger capacity of non-specific binding. Others may argue for the use of magnetic beads because of the greater quantity of antibody required to saturate the total binding capacity of agarose beads, which would obviously be an economical disadvantage of using agarose. While these arguments are correct outside the context of their practical use, these lines of reasoning ignore two key aspects of the principle of immunoprecipitation that demonstrates that the decision to use agarose or magnetic beads is not simply determined by binding capacity.
Sources: en.wikipedia.org
Rumors also surfaced in February 2022 that El Mencho died in a private hospital in Guadalajara. This would later be backed by narcomantas (banners displaying warnings to police and other cartels) which appeared around the city of Colima, and which were written by Mezcales, which up until this report of El Mencho's death, acted as the CJNG's local enforcers.
== Awards == Major Awards 1. Young Scientist Medal (1988), by the Indian Science Congress Association, India. 2. INSA Young Scientist Medal (1991), by the Indian National Science Academy, New Delhi. 3. CRSI Bronze Medal (2002), by the Chemical Research Society of India. 4. MRSI Medal (2007), by Material Research Society of India. 5. Shanti Swarup Bhatnagar Prize (2007), awarded by CSIR, Govt. India. 6. DAE Outstanding Researcher Award (2009), awarded by Dept. Atomic Energy, Govt. India. 7. Thomson Reuters Research Excellence-India Research Front Award (2009). 8. The Infosys Prize for Physical Sciences 2012 by Infosys Science Foundation. 9. Khwarizmi International Award 2012 by Iranian Organisation for Science and Technology. 10. Swadeshi Innovation Award 2012 by the Swadeshi Science Movement, Kerala. 11. Sri Vidyadhiraja Samskrithi Puraskaram 2013 by Panmana Ashram, Quilon, Kerala. 12. CRSI Silver Medal 2013 by Chemical Research Society of India. 13. TWAS Chemistry Prize 2013 by The World Academy of Sciences, Trieste, Italy. 14. ISAS National Award for Excellence in Science and Technology 2014 by Indian Society of Analytical Scientists. 15. CHEMTECH CEW Award 2015 for Leadership and Excellence in Research and Development. 16. J. C. Bose National Fellowship, 2015, DST, Govt. India. 17. Web of Science-India Research Excellence-Citation Award 2017 by Clarivate Analytics. 18. MRSI Distinguished Lectureship Award, 2019-20, by Materials Research Society of India. 19. Goyal Prize for Chemical Science, 2019, by Kurukshetra University. Other Honors 1.
== External links == skel&wallsabd at The Anatomy Lesson by Wesley Norman (Georgetown University) "Anatomy photo:35:os-0108". SUNY Downstate Medical Center. Archived from the original on March 5, 2016. (before removing skin) "Anatomy photo:35:06-0101". SUNY Downstate Medical Center. Archived from the original on March 5, 2016. (after removing skin) "Anatomy diagram: 03281.000-2". Roche Lexicon - illustrated navigator. Elsevier. Archived from the original on 2014-01-01.
=== Pregnancy and breastfeeding === SSRI use in pregnancy has been associated with a variety of risks with varying degrees of proof of causation. As depression is independently associated with negative pregnancy outcomes, determining the extent to which observed associations between antidepressant use and specific adverse outcomes reflect a causative relationship has been difficult in some cases. In other cases, the attribution of adverse outcomes to antidepressant exposure seems fairly clear. SSRI use in pregnancy is associated with an increased risk of spontaneous abortion of about 1.7-fold. Use is also associated with preterm birth. According to some researches, decreased body weight of the child, intrauterine growth retardation, neonatal adaptive syndrome, and persistent pulmonary hypertension also was noted. A systematic review of the risk of major birth defects in antidepressant-exposed pregnancies found a small increase (3% to 24%) in the risk of major malformations and a risk of cardiovascular birth defects that did not differ from non-exposed pregnancies. Other studies have found an increased risk of cardiovascular birth defects among depressed mothers not undergoing SSRI treatment, suggesting the possibility of ascertainment bias, e.g. that worried mothers may pursue more aggressive testing of their infants. Another study found no increase in cardiovascular birth defects and a 27% increased risk of major malformations in SSRI-exposed pregnancies. The FDA stated on July 19, 2006, that nursing mothers on SSRIs must discuss treatment with their physicians.
Apixaban, sold under the brand name Eliquis among others, is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation through directly inhibiting factor Xa. It is used as an alternative to warfarin to prevent blood clots following hip or knee replacement and in those with a history of prior clots and does not require monitoring by blood tests or dietary restrictions. It is taken by mouth. Common side effects include bleeding and nausea. Other side effects may include bleeding around the spine and allergic reactions. Use is not recommended during pregnancy or breastfeeding. Use appears to be relatively safe in those with mild kidney problems. Compared to warfarin it has fewer interactions with other medications. It is a direct factor Xa inhibitor. In 2007, Pfizer and Bristol-Myers Squibb began the development of apixaban as an anticoagulant. Apixaban was approved for medical use in the European Union in May 2011, and in the United States in December 2012. It is on the World Health Organization's List of Essential Medicines. In 2023, it was the 28th most commonly prescribed medication in the United States, with more than 19 million prescriptions. It is available as a generic medication, although not in the United States.
Sources: en.wikipedia.org
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.
Reverse-phase HPLC with ultraviolet detection at 214 nm is common. Mass spectrometry is used to confirm molecular identity and detect modifications. Immunoassays exist but may not distinguish the intact peptide from fragments.